Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
2cureX AB is a biotechnology company that focuses on the development of innovative diagnostic and testing methodologies aimed at improving cancer treatment outcomes. The primary function of the company is to advance its proprietary IndiTreat technology, which is designed to better predict the efficacy of cancer therapies for individual patients. This allows clinicians to tailor treatment plans based on the specific responsiveness of a patient's cancer cells, potentially increasing the success rate of cancer treatments. By analyzing the impact of various drugs on cancer cells in a laboratory setting, IndiTreat aims to guide oncologists in selecting the most effective treatment options. 2cureX AB plays a pivotal role within the healthcare sector by addressing critical gaps in personalized cancer therapy, offering a tool that aligns with the global trend toward precision medicine. Headquartered in Europe, 2cureX continues to garner attention for its contribution to enhancing clinical decision-making and improving patient outcomes in oncology.
€0.14
+€0.00 (+0.58%)
EOD Aug 14, 2026
ROIC dropped from -9.01% to -72.79%, capital efficiency is deteriorating. Negative free cash flow of -kr 5M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 0.00
Net Income (TTM)
-kr 5M
▲ +88.1% YoY
Op. Margin
—
ROIC
-72.79%
▼ -63.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 5M
▼ -137.1% YoY
Op. Cash Flow (TTM)
-kr 5M
▼ -139.2% YoY
Net Debt
-kr 5M
Net Cash Position
Cash & Equiv.
kr 5M
Continue Research
2cureX AB (2CUREX.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, 2cureX AB scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
2cureX AB scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -72.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh 2CUREX.XSTO's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.